| Chen, Jean |
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk |
|
|
| Active, not recruiting | 3 | 2749 | Europe, US, RoW | Orforglipron, LY3502970, Insulin Glargine | Eli Lilly and Company | Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease | 09/25 | 01/26 | | |
| Active, not recruiting | 3 | 15374 | Europe, Canada, Japan, US, RoW | Tirzepatide, LY3298176, Placebo | Eli Lilly and Company | Obesity, Overweight | 10/27 | 10/27 | | |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
ZONE, NCT05762107: A Study of the Effect of ZT-01 on Night-time Hypoglycemia in Type 1 Diabetes |
|
|
| Recruiting | 2 | 186 | Canada, US | Placebo, ZT-01, 7 mg, ZT-01, 15 mg, ZT-01, 22 mg | Zucara Therapeutics Inc. | Type 1 Diabetes Mellitus with Hypoglycemia | 06/25 | 07/25 | | |
NCT06273124: Investigational Extended Wear Insulin Infusion Set in People With Type 1 Diabetes |
|
|
| Completed | N/A | 260 | US | SteadiSet Extended Wear Infusion Set | Tandem Diabetes Care, Inc., Jaeb Center for Health Research | Type1diabetes | 12/24 | 12/24 | | |
NCT06719531: SYNERGY PLUS: Evaluation of Next Generation Sensors (NGS) and Algorithm in Patients with Type 1 and Type 2 Diabetes |
|
|
| Not yet recruiting | N/A | 1500 | US | Continuous Glucose Monitoring | Medtronic Diabetes | Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus | 12/25 | 12/25 | | |
| Recruiting | N/A | 925 | US | Blood glucose meter, Eversense CGM System | Senseonics, Inc. | Diabetes | 03/26 | 03/26 | | |
| Malik, Arshad Nawaz AN |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
NCT05769608: A Pivotal Study to Evaluate the Efficacy of Lorundrostat in Subjects with Uncontrolled Hypertension on a Standardized Antihypertensive Medication Regimen |
|
|
| Active, not recruiting | 2 | 285 | US | Placebo, lorundrostat Dose 1, lorundrostat Dose 2 | Mineralys Therapeutics Inc. | Hypertension | 01/25 | 02/25 | | |
TRANSFORM, NCT06112418: A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events |
|
|
| Recruiting | N/A | 7500 | US | The Cleerly CAD Staging System | Cleerly, Inc., CPC Clinical Research | Diabetes Mellitus, Type 2, PreDiabetes, Metabolic Syndrome | 03/29 | 03/29 | | |
| Philipson, Lou |
OPTI-2, NCT06238778: Phase 2b Trial Comparing HDV-Insulin Lispro to Insulin Lispro in Adults With Type 1 Diabetes Receiving Insulin Degludec |
|
|
| Recruiting | 2 | 230 | US | HDV-Lispro, HDV-L, Lispro, LIS | Diasome Pharmaceuticlas, Inc. | Diabetes Mellitus, Type 1 | 06/25 | 12/25 | | |
